Excision repair cross-complimentary group 1

Genetic variation in ERCC1 and XPF genes and breast cancer risk

X. H. Pei, Yang, Z., Lv, X. Q., and Li, H. X., “Genetic variation in ERCC1 and XPF genes and breast cancer risk”, vol. 13, pp. 2259-2267, 2014.

Breast cancer is one of the most frequently diagnosed cancer in women worldwide, and we conducted a case-control study by genotyping seven potentially functional SNPs, three in ERCC1 and four in XPF, in a Chinese population of 417 breast cancer cases and 417 cancer-free controls. Three SNPs in ERCC1 and four SNPs in XPF were genotyped by using the Taqman Universal PCR Master Mix in the GeneAmp^® PCR System 9700 with Dual 384-Well Sample Block Module, and assays were performed on a 384-well plate on the Sequenom MassARRAY platform.

Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer

L. Liu, Li, C. H., Jin, T. F., and Xu, D. Y., “Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer”, vol. 13, pp. 8722-8728, 2014.

We conducted a cohort study to investigate the role of 2 single-nucleotide polymorphisms of the excision repair cross-complimentary group 1 (ERCC1) gene polymorphism in response to chemotherapy and clinical outcomes of gastric cancer. A total of 231 patients with newly diagnosed and histopathologically confirmed primary gastric cancer participated in the study. ERCC1 rs11615 and rs3212986 were genotyped. Individuals with the ERCC1 rs11615 TT genotype and the T allele showed a significant poorer response to chemotherapy compared to the wild-type genotype.